Metadatos
Mostrar el registro completo del ítemCompartir este ítem
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
Idioma
EN
Article de revue
Este ítem está publicado en
Antimicrobial Agents and Chemotherapy. 2019-01-01, vol. 63, n° 1
Resumen en inglés
A clinical isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from ...Leer más >
A clinical isolate resistant to all β-lactams, including ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed an increased hydrolytic activity toward carbapenems and to ceftolozane and a decreased susceptibility to β-lactamase inhibitors compared to GES-1, except for avibactam. We show here that resistance to ceftolozane-tazobactam may occur through acquisition of a specific ESBL in but that ceftazidime-avibactam combination remains an effective alternative.< Leer menos
Palabras clave en inglés
Amino Acid Substitution
Anti-Bacterial Agents
Azabicyclo Compounds
Carbapenems
Ceftazidime
Cephalosporins
Drug Combinations
Gene Expression
Humans
Microbial Sensitivity Tests
Pseudomonas Infections
Pseudomonas aeruginosa
Tazobactam
beta-Lactam Resistance
beta-Lactamases
Centros de investigación